PMID- 21961329
OWN - NLM
STAT- MEDLINE
DCOM- 20111108
LR  - 20131121
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 83
IP  - 8
DP  - 2011
TI  - [Prolongation of enoxaparin therapy to one month promotes recanalization of the 
      occlusively thrombosed deep veins].
PG  - 33-7
AB  - AIM: To compare effects of prolongation of the treatment with therapeutic doses 
      of enoxaparin to 1 month on recanalization of occlusively thrombosed deep veins 
      (OTDV) of the limbs with results of standard therapy with unfractionated heparin 
      (UFH). Both treatments were followed by warfarin administration. MATERIAL AND 
      METHODS: Thirty patients were selected from 111 patients with a history of deep 
      vein thrombosis (DVT) and/or pulmonary artery embolism according to the following 
      criteria: the presence of occlusive thrombosis of one deep vein minimum; the 
      absence of DVT for 12 months of follow-up. Patients of group 1 (n = 15) received 
      standard therapy (UFH for at least 5 days) with switch to warfarin. Patients of 
      group 2 (n = 15) received therapeutic doses of enoxaparin (1 mg/kg each 12 hours) 
      for 30 days minimum with switch to warfarin. Follow-up was 12 months. Ultrasonic 
      duplex angioscanning of the limbs was made at baseline, 1, 3, 6 and 12 months 
      after treatment start. RESULTS: After follow-up month 1, 3 and 6 number of 
      patients with occlusive DVT was significantly less in group 2. All the patients 
      given enoxaparin achieved recanalization of OTDV within 3 months of treatment. 
      OTDV recanalization was not achieved in 20% patients of group 1 even 12 months 
      after treatment start. CONCLUSION: Prolongation of enoxaparin treatment to 1 
      month followed by warfarin treatment is superior to standard UFH treatment 
      followed by warfarin in providing recanalization of OTDV within 3 months of 
      treatment. Moreover, this treatment predicts persistence of recanalization within 
      12 months of anticoagulant therapy.
FAU - Vorob'eva, N M
AU  - Vorob'eva NM
FAU - Panchenko, E P
AU  - Panchenko EP
FAU - Ermolina, O V
AU  - Ermolina OV
FAU - Balakhonova, T V
AU  - Balakhonova TV
FAU - Dobrovol'skii, A B
AU  - Dobrovol'skii AB
FAU - Titaeva, E V
AU  - Titaeva EV
FAU - Khasanova, Z B
AU  - Khasanova ZB
FAU - Postnov, A Iu
AU  - Postnov AIu
FAU - Kirienko, A I
AU  - Kirienko AI
LA  - rus
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 5Q7ZVV76EI (Warfarin)
SB  - IM
MH  - Anticoagulants/*administration & dosage/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Enoxaparin/*administration & dosage/therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pulmonary Embolism/blood/etiology/prevention & control
MH  - Treatment Outcome
MH  - Venous Thrombosis/blood/complications/*drug therapy
MH  - Warfarin/administration & dosage/therapeutic use
EDAT- 2011/10/04 06:00
MHDA- 2011/11/09 06:00
CRDT- 2011/10/04 06:00
PHST- 2011/10/04 06:00 [entrez]
PHST- 2011/10/04 06:00 [pubmed]
PHST- 2011/11/09 06:00 [medline]
PST - ppublish
SO  - Ter Arkh. 2011;83(8):33-7.